Temelimab
What is Temelimab?
Temelimab, also known as GNbAC1, is a new treatment under investigation for relapsing-remitting and progressive multiple sclerosis (MS) (1). It is a humanized IgG4 monoclonal antibody that targets the MSRV-Env protein and neutralizes its action (3). Temelimab is taken as an intravenous infusion (drip) (1).
Dosage
The manufacturer of temelimab has set up a study to evaluate higher doses of the medication in people with relapsing-remitting MS that is progressing in the absence of relapses (1). However, a standard dose for temelimab remains undefined.
Side Effects
Preliminary results from a study on temelimab have shown that higher doses of the medication were well-tolerated with no treatment-related discontinuations of treatment after one year (1). Additionally, a systematic review of Phase I, Phase II-a, and Phase II-b trials demonstrated the safety and effectiveness of temelimab, with a statistically non-significant risk ratio of adverse events compared to the placebo group (3).
Interactions
There is no information available on potential interactions between temelimab and other medications or supplements. Further research is needed to understand the full scope of temelimab's interactions.
How well studied is Temelimab in humans?
Temelimab has been the subject of several clinical trials, including Phase I, Phase II-a, and Phase II-b trials, which have demonstrated its safety and effectiveness (3). However, more research is needed to fully understand the potential benefits and risks of temelimab for the treatment of multiple sclerosis.
Citations:
(1) https://mstrust.org.uk/a-z/temelimab
(2) https://pubmed.ncbi.nlm.nih.gov/34240656/
(3) https://pubmed.ncbi.nlm.nih.gov/35344907/
(4) https://twitter.com/narutofess/status/1305402785702141952
(5) https://reference.medscape.com/drug/sovaldi-sofosbuvir-999890
(6) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029125/
Temelimab used in MS
https://multiplesclerosisnewstoday.com/gnbac1-for-rrms/
